PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.23%
EBIT growth above 1.5x RVPH's 5.85%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
22.23%
Operating income growth above 1.5x RVPH's 7.11%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
18.34%
Net income growth above 1.5x RVPH's 5.90%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
32.95%
EPS growth above 1.5x RVPH's 7.69%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
32.95%
Diluted EPS growth above 1.5x RVPH's 7.69%. David Dodd would see if there's a robust moat protecting these shareholder gains.
21.91%
Share count expansion well above RVPH's 2.47%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
21.91%
Diluted share count expanding well above RVPH's 2.47%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
46.02%
OCF growth 1.25-1.5x RVPH's 38.83%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
46.06%
FCF growth 1.25-1.5x RVPH's 38.83%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8783.56%
Negative 10Y OCF/share CAGR while RVPH stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
85.25%
5Y OCF/share CAGR above 1.5x RVPH's 21.52%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
76.39%
3Y OCF/share CAGR 1.25-1.5x RVPH's 53.59%. Bruce Berkowitz might see if strategic cost controls or product mix drove recent gains.
-13944.86%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
85.03%
5Y net income/share CAGR 1.25-1.5x RVPH's 60.51%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
64.22%
3Y net income/share CAGR 1.25-1.5x RVPH's 58.01%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
5293.49%
Equity/share CAGR of 5293.49% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
188.65%
Equity/share CAGR of 188.65% while RVPH is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
367.41%
Positive short-term equity growth while RVPH is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.58%
Negative asset growth while RVPH invests at 64.40%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-38.36%
We have a declining book value while RVPH shows 89.95%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-22.17%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-22.47%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.